Bausch and Lomb has launched FineVision and FineVision Toric Intraocular Lenses to Australian ophthalmologists – positioning it as a trifocal diffractive intraocular lens that can be used to treat presbyopia and cataract.
The IOLs were launched at dinner events in Sydney and Melbourne during July and at the 18th AUSCRS conference in Port Douglas.
FineVision is a trifocal intraocular lens that features a series of rings which diffract light to provide far, intermediate and near vision. This is in contrast to monofocal or bifocal lenses, which allow focus in one or two distinct visual scenarios.
Dr. Eric Mertens, who currently serves as Director and Ophthalmic Surgeon of the Medipolis Eye Center in Belgium, recounted his experiences with FineVision at all three launch events. He has implanted thousands of multifocal IOLs and has been implanting FineVision IOLs since they were launched in Europe in 2011 and more recently, FineVision Torics. Having performed over 1,400 FineVision implants, Dr. Mertens shared his clinical results, including visual outcomes and higher order aberration measurements and provided a comparison to other bifocal and multifocal IOLs currently on the market. Additionally, he showed a video demonstrating the ease of implantation.
Comparing FineVision IOLs with multifocal and bifocal lenses, Dr. Mertens concluded that FineVision Trifocals provide excellent intermediate vision without compromising distance or near acuities, as well as achieving more favourable near vision and superior image quality. He noted that the enhancement rate was lower with FineVision.
Dr. Mertens said FineVision Toric IOLs offered “good rotational stability; an easy IOL calculator and were easy to position in the correct axis”. He said FineVision IOLs were most suited to patients who were motivated to be free from spectacles with realistic expectations for visual outcomes. Patients with very high expectations were more challenging, he said, and patients with unrealistic expectations or ocular pathologies, were more suited to monofocal IOLs.